Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 7:01 p.m.

    📋 COHERUS BIOSCIENCES, INC. (CHRS) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 16:25:29

    Event Type: Financial Results

    Event Details:

    Coherus BioSciences Inc (CHRS) Reports Q3 2022 Financial Results Coherus BioSciences Inc (CHRS) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 60151
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 275924
      • planned for early October 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Costs And Expenses Selling General Administrative 40.34K 100.03K $-59.68K -59.67%
    Costs And Expenses Loss From Operations -24.16K -124.94K $100.77K +80.66%
    Costs And Expenses Interest Expense -5.75K -15.55K $9.80K +63.04%
    Costs And Expenses Other Income Net 11.00 475.00 $-464.00 -97.68%
    Income Tax Provision Net Loss -29.90K -146.23K $116.33K +79.55%
    Assets Other Assets 47.11K 47.11K $0.00 +0.00%
    Liabilities And Stockholders Equity Deficit Term Loans 196.04K 196.04K $0.00 +0.00%
    Net Loss Per Share -0.24 -1.46 $1.22 +83.56%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Coherus BioSciences Inc
    • CIK: 0001512762
    • Ticker Symbol: CHRS
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories